-
公开(公告)号：KR101200189B1
公开(公告)日：2012-11-13
申请号：KR1020070076188
申请日：2007-07-30
Applicant: 재단법인서울대학교산학협력재단 , 중앙대학교 산학협력단
Abstract: 본 발명은 면역침강법을 활용한 결합 단백질들의 탐색방법에 관한 것으로, 특정단백질과 결합하는 새로운 단백질을 발굴하는 방법을 제시함에 있어 종래의 면역침강법을 보완하여, 한 번의 면역침강실험으로 여러 종류의 단백질군들과의 결합여부를 확인할 수 있는 방법에 관한 것이다. 이를 위하여 본 발명은 미끼단백질에 결합하는 단백질들의 탐색방법에 있어서, 미끼단백질과의 결합여부를 확인하고 싶은 단백질을 조합하여 항체 풀 세트를 구성하고 각각의 항체의 정보를 얻어 기준이 되는 룰러를 마련하고, 상기 항체 풀세트를 사용해 미끼단백질과의 웨스턴 블랏을 시행하여 결과를 얻고, 상기 웨스턴 블랏의 결과를 상기 항체 풀 세트의 룰러와 비교하여 결합여부를 확인하는 과정을 포함한다.
면역침강, SDS-PAGE, 웨스턴 블랏-
公开(公告)号：KR101145061B1
公开(公告)日：2012-05-11
申请号：KR1020070076217
申请日：2007-07-30
Applicant: 재단법인서울대학교산학협력재단 , 중앙대학교 산학협력단
Abstract: A pharmaceutical composition is provided to increase transcriptional activity of p53 and cell death by hindering analysis of p53 by MDM2 and to have anticancer effect suppressing dysplasia and carcinogenesis of cell. A pharmaceutical composition shows anticancer effect by including p19Ras protein as active component, uniting p19Ras protein with p53 protein and increasing activity of the p53 protein. The p19Ras protein is indicated as amino acid sequence of a sequence listing sequence number 1. The cancer is breast cancer, ovarian cancer, liver cancer, lung cancer, colon carcinoma or prostate cancer. An activity of the p53 protein is increased by hindering ubiquitination of p53 by MDM2.
-
公开(公告)号：KR3004665590000S
公开(公告)日：2007-10-24
申请号：KR3020070027180
申请日：2007-06-25
Applicant: 재단법인서울대학교산학협력재단
-
Patent Agency Ranking4.发明公开ｐ19ｒａｓ 유전자를 포함하는 발현벡터 또는 ｐ19ｒａｓ단백질을 유효성분으로 하는 암의 예방 또는 치료용 약학적조성물 无效用于治疗或预防包含含有P19RAS基因或P19RAS蛋白作为有效成分的表达载体的癌症的药物组合物
公开(公告)号：KR1020090111726A
公开(公告)日：2009-10-27
申请号：KR1020080037461
申请日：2008-04-22
Applicant: 중앙대학교 산학협력단 , 재단법인서울대학교산학협력재단
CPC classification number: A61K38/1709 , A61K48/00 , C07K14/47 , C12N15/66
Abstract: PURPOSE: A pharmaceutical composition for preventing and treating cancer, which contains an expression vector containing p19ras gene or p19ras protein is provided to suppress abnormal proliferation. CONSTITUTION: A pharmaceutical composition for preventing or treating cancer contains an expression vector of p19ras gene or p19ras protein. The p19ras gene is denoted by sequence of the sequence number 1. The cancer is a cancer in which NSE is overexpressed.
Abstract translation: 目的：提供含有含有p19ras基因或p19ras蛋白质的表达载体的用于预防和治疗癌症的药物组合物，以抑制异常增殖。 构成：用于预防或治疗癌症的药物组合物含有p19ras基因或p19ras蛋白的表达载体。 p19ras基因以序列号1的序列表示。癌症是NSE过表达的癌症。
-
公开(公告)号：KR3004665580000S
公开(公告)日：2007-10-24
申请号：KR3020070027179
申请日：2007-06-25
Applicant: 재단법인서울대학교산학협력재단
-
公开(公告)号：KR1020090111728A
公开(公告)日：2009-10-27
申请号：KR1020080037463
申请日：2008-04-22
Applicant: 중앙대학교 산학협력단 , 재단법인서울대학교산학협력재단
CPC classification number: A61K38/1709 , C07K14/4703 , Y10S514/912
Abstract: PURPOSE: A pharmaceutical composition for preventing and treating NRL-mediated eye disease is provided to control NRL activation. CONSTITUTION: A pharmaceutical composition for preventing and treating NRL-mediated eye diseases contains JNK1 as an active ingredient. The JNK1 has an amino acid of the sequence number 1. The NRL has an amino acid of the sequence number 3. The pharmaceutical composition contains a recombinant vector as an active ingredient with a polynucleotide encoding JNK1 or promoter.
Abstract translation: 目的：提供用于预防和治疗NRL介导的眼病的药物组合物以控制NRL活化。 构成：用于预防和治疗NRL介导的眼部疾病的药物组合物含有JNK1作为活性成分。 JNK1具有序列号1的氨基酸.NNL具有序列号3的氨基酸。药物组合物含有作为活性成分的重组载体，其具有编码JNK1或启动子的多核苷酸。
-
公开(公告)号：KR1020090012416A
公开(公告)日：2009-02-04
申请号：KR1020070076217
申请日：2007-07-30
Applicant: 재단법인서울대학교산학협력재단 , 중앙대학교 산학협력단
Abstract: A pharmaceutical composition is provided to increase transcriptional activity of p53 and cell death by hindering analysis of p53 by MDM2 and to have anticancer effect suppressing dysplasia and carcinogenesis of cell. A pharmaceutical composition shows anticancer effect by including p19Ras protein as active component, uniting p19Ras protein with p53 protein and increasing activity of the p53 protein. The p19Ras protein is indicated as amino acid sequence of a sequence listing sequence number 1. The cancer is breast cancer, ovarian cancer, liver cancer, lung cancer, colon carcinoma or prostate cancer. An activity of the p53 protein is increased by hindering ubiquitination of p53 by MDM2.
Abstract translation: 提供药物组合物，通过抑制MDM2对p53的分析和抑制细胞发育不良和致癌作用具有抗癌作用，增加p53的转录活性和细胞死亡。 药物组合物通过包括p19Ras蛋白作为活性成分显示抗癌作用，将p19Ras蛋白与p53蛋白质结合并增加p53蛋白的活性。 p19Ras蛋白被表示为序列表序列号1的氨基酸序列。癌症是乳腺癌，卵巢癌，肝癌，肺癌，结肠癌或前列腺癌。 通过抑制MDM2对p53的泛素化，p53蛋白的活性增加。
-
公开(公告)号：KR1020090012407A
公开(公告)日：2009-02-04
申请号：KR1020070076188
申请日：2007-07-30
Applicant: 재단법인서울대학교산학협력재단 , 중앙대학교 산학협력단
Abstract: A method for searching proteins uniting with bait protein is provided to confirm bond with various kinds of protein families through one immunoprecipitation experiment. A method for searching proteins uniting with bait protein comprises steps of: assembling protein which wants to confirm bond with the bait protein and making antibody full set; implementing Western blot with the bait protein using the antibody full set and obtaining a result; comparing a result of the Western blot with a ruler of the antibody full set and confirming whether bond is performed or not. A method for manufacturing the ruler comprises steps of: loading cell lysate of cell strain for expressing the bait protein and separating protein within the cell lysate by using SDS-PAGE; assembling the protein which wants to confirm bond with the bait protein and making the antibody full set; implementing Western blot using antibody of the antibody full set; and comparing results with a size marker and linearizing and indicating it.
Abstract translation: 提供一种搜索与诱饵蛋白结合的蛋白质的方法，通过一次免疫沉淀实验确认与各种蛋白质家族的结合。 搜索与诱饵蛋白结合的蛋白质的方法包括以下步骤：组装蛋白质，其需要确认与诱饵蛋白质的结合并使抗体完整; 使用抗体全套实施诱饵蛋白的Western印迹并获得结果; 将Western印迹的结果与抗体全集的标尺进行比较，并确认是否进行结合。 制造尺的方法包括以下步骤：通过使用SDS-PAGE，加载用于表达诱饵蛋白的细胞株的细胞裂解物和细胞裂解物内的蛋白质分离; 组装需要确认与诱饵蛋白质结合并使抗体完整的蛋白质; 使用抗体全抗体实施蛋白质印迹; 并将结果与大小标记进行比较，并进行线性化和指示。
-
-
-
-
-
-
-
Search Results
8
records
(took 0.037 seconds)
